Lipocine Inc. (LPCN): Shareholders' Equity
$14.48M
As of 2025-12-31
$21.77M
As of 2026-06-30
-25.9%
3-year compound annual growth
-1.2%
5-year compound annual growth
-10.1%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.48M | -31.1% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $21.00M | +3.1% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $20.37M | -42.8% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $35.63M | -21.8% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $45.57M | +197.0% | 2023-03-10, Balance as of period end |
| 2020-12-31 | $15.34M | +144.0% | 2022-03-09, Balance as of period end |
| 2019-12-31 | $6.29M | -33.3% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $9.43M | -50.3% | 2020-03-13, Balance as of period end |
| 2017-12-31 | $18.98M | -27.0% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $26.02M | -38.0% | 2019-03-06, Balance as of period end |
| 2015-12-31 | $41.99M | +59.3% | 2018-03-12, Balance as of period end |
| 2014-12-31 | $26.36M | -41.2% | 2017-03-06, Balance as of period end |
| 2013-12-31 | $44.82M | +743.2% | 2015-03-11, Balance as of period end |
| 2012-12-31 | $5.32M | n/m | 2014-03-31, Balance as of period end |
| 2011-12-31 | $24.8K | n/a | 2013-02-26, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Lipocine Inc. (LPCN) | 2025-12-31 | $14.48M | -31.1% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $493.40M | +40.0% |
| Bio Essence Corp (BIOE) | 2025-12-31 | -$2.07M | n/m |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $9.09M | +2.7% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $33.01M | n/m |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $3.83M | -24.2% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$15.94M | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.83M | -34.5% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | -$126.24M | n/m |
Compare LPCN, DNTH, BIOE, KRSA side by side · Screen every company in Pharmaceutical Preparations ↗